Multi-marker Approach for Risk Assessment in PAH

Key facts

Sponsor

Wuhan Asia Heart Hospital

Principal Investigator

Qiu Qiu

Wuhan Asian Heart Hospital

Enrollment

500 enrolled

Eligibility

1-85 years · All sexes

Timeline

2017 – 2025

Study locations (1)

• Wuhan Asian Heart Hospital, Wuhan, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07593027
  A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.
  ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
• RECRUITINGNANCT07563322
  Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension
  Vanderbilt University Medical Center
• ACTIVE NOT RECRUITINGNANCT07391228
  Cognitive Alterations in Pulmonary Arterial Hypertension (PAH)
  Alessandra Gorini
• RECRUITINGNANCT06871293
  Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19
  Fundación Cardioinfantil Instituto de Cardiología
• RECRUITINGNANCT06911632
  Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
  Tempus AI
• ACTIVE NOT RECRUITINGPHASE3NCT06274801
  Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
  GB002, Inc.
• RECRUITINGPHASE2NCT05937854
  Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
  VA Office of Research and Development
• RECRUITINGNCT06291389
  Intraoperative Peak Airway Pressure Changes on Postoperative Pulmonary Function After Muscle Plication
  Al-Azhar University

See all trials for Pulmonary arterial hypertension →